Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(6)
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)
Stable angina: management (CG126)
Acne vulgaris: management (NG198)
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
Brain tumours (primary) and brain metastases in over 16s (NG99)
Inducing labour (NG207)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 1 · 2019–2026
Showing all 30 studies, sorted by most relevant.
M. Ouzir, Sara El Bernoussi, M. Tabyaoui, et al.
Comprehensive reviews in food science and food safety, 2021
- Cosmetics
- Chromatography, Supercritical Fluid
- Plant Oils
Amin Pirali Najafabadi, Mehrab Pourmadadi, F. Yazdian, et al.
Journal of Drug Delivery Science and Technology, 2023
The rapid rise of cancer worldwide demonstrates the importance of treatment strategies. In addition to reduce the side effects of conventional treatments, targeted drug delivery systems increase performance and effectiveness. In this research, nanocarriers comprising gelatin (G)-polyvinylpyrrolidone (PVP) coated graphene oxide (GO) were prepared for the first time. The nanocarries were loaded with quercetin (QC) drug and a dual nanoemulsion water/oil/water with bitter almond oil was developed as a membrane around the nanocomposite to control further drug release. XRD, FTIR, FESEM, and DLS analysis confirmed the success of the nanocomposite synthesis and drug loading. The resulting pH-sensitive drug delivery system showed an 87.5% encapsulation efficiency and a 45% drug loading, which are among the highest values reported up to date. The zeta potential of the nanocomposites was about −40 mV, indicating good stability. The release kinetics of the drug followed the Higuchi model, and the presence of a dual nanoemulsion resulted in better drug entrapping efficiency, drug controlled release and long-term release. MTT assay and flow cytometry methods revealed a rate of cancer cell death of 53.14%, which was 36.51% in the apoptotic phase. Taking into account the results obtained herein, PVP-G-GO-QC can be considered as a new promising system for cancer treatment.
Abstract licence: CC BY-NC-ND
J. Hoyos-Leyva, L. Bello‐Pérez, J. E. Agama-Acevedo, et al.
LWT, 2019
Sonia Ramos-Gómez, M. D. Busto, N. Ortega
Molecules, 2023
- Prunus dulcis
- Corylus
- Olive Oil
Virgin olive oil (VOO), characterized by its unique aroma, flavor, and health benefits, is subject to adulteration with the addition of oils obtained from other edible species. The consumption of adulterated olive oil with nut species, such as hazelnut or almond, leads to health and safety issues for consumers, due to their high allergenic potential. To detect almond and hazelnut in olive oil, several amplification systems have been analyzed by qPCR assay with a SYBR Green post-PCR melting curve analysis. The systems selected were Cora1F2/R2 and Madl, targeting the genes coding the allergenic protein Cor a 1 (hazelnut) and Pru av 1 (almond), respectively. These primers revealed adequate specificity for each of the targeted species. In addition, the result obtained demonstrated that this methodology can be used to detect olive oil adulteration with up to 5% of hazelnut or almond oil by a single qPCR assay, and with a level as low as 2.5% by a nested-qPCR assay. Thus, the present research has shown that the SYBR-based qPCR assay can be a rapid, precise, and accurate method to detect adulteration in olive oil.
Abstract licence: CC BY
Mohammad Arab Chamchangi, S. Abdollahi, Zeinab Raoufi, et al.
International journal of biological macromolecules, 2024
- Anti-Bacterial Agents
- Cellulose
- Emulsions
Francisca Salinas, Renata Vardanega, Carolina Espinosa-Álvarez, et al.
Journal of Supercritical Fluids, 2020
Sonia Fathi-karkan, Abbas Rahdar, Z. Keshavarzi, et al.
BioNanoScience, 2024
J. J. Burbano, M. J. Correa
International Journal of Food Science & Technology, 2024
F. F. Dias, Bianca Ferraz Teixeira, Ameer Y. Taha, et al.
Journal of the American Oil Chemists' Society, 2025
Abstract Although aqueous and enzymatic extractions are solvent‐free alternatives for extracting oil and proteins from almond flour, most of the extracted oil becomes entrapped in an emulsion and needs demulsification for recovery. To assess how extraction and demulsification methods impact yields and quality, a lipidomic approach was used to investigate the effects of aqueous and enzymatic extractions processes and recovery strategies, including pH‐shift and protease addition, on almond oil quality. Liquid chromatography‐mass spectrometry, conventional oxidation markers (peroxide value, p‐anisidine), fatty acid profile, lipid class, total phenolic content and antioxidant activity were employed to determine the combined impact of extraction and recovery methods on lipid quality and composition. Peroxide value (1.8–2.0 mEq/kg oil), p‐anisidine (0.1–0.4), and fatty acid composition of the oils (18:1 72%–75%, 18:2 22%–25%, 16:0 4%–5%) showed no significant changes based on extraction and recovery methods. However, oxylipin analysis demonstrated that the solvent‐extracted oil had higher levels of 13‐hydroxyoctadecadienoic acid (13‐HODE) and 12(13)‐epoxyoctadecenoic acid (12(13)‐EpOME) compared to aqueous and enzymatically extracted oils, regardless of the demulsification method. Additionally, the solvent‐extracted oil exhibited lower phenolic content and antioxidant capacity. This work provides valuable insights into how environmentally friendly extraction and recovery methods impact almond oil quality, contributing to processing optimization.
Abstract licence: CC BY
M. Kozłowska, Diana Mańko-Jurkowska, Bartłomiej Zieniuk, et al.
Molecules, 2025
- Prunus dulcis
- Plant Oils
- Solvents
The aim of the study was to compare the quality of almond oils obtained using different extraction methods, including cold solvent extraction, Soxhlet extraction, and the Folch method. Oils were extracted from four commercially available almond-based products—unpeeled almonds, blanched almonds, almond flakes, and almond protein concentrate—and compared with a commercially refined almond oil. The extracted oils were analyzed for their fatty acid (FA) composition and selected quality parameters, including acid value, peroxide value, p-anisidine value, the TOTOX index, and specific extinction coefficients (K232 and K268). Based on the FA profiles, health-related indices such as atherogenic index, thrombogenic index, and hypocholesterolemic/hypercholesterolemic ratio were also calculated. Additionally, the oxidative stability of the oils was assessed using an accelerated method—pressure differential scanning calorimetry. The obtained results demonstrated that the extraction method had a stronger influence on almond oil quality than the type of raw material. Oil extracted from unpeeled almonds using Soxhlet and cold solvent techniques showed better oxidative stability and more favorable FA profiles, while oils obtained using the Folch method and commercial refined oils exhibited higher levels of primary and secondary oxidation products. These findings were further supported by statistical analyses, which revealed distinct groupings based on oxidation indices and lipid composition.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.